CellCentric
Company

CellCentric

Biotechnology Little Chesterford, United Kingdom 46 employees
Employees
46
Contacts
2
Emails
2
Phones
1

CellCentric Overview

Headquarters
Little Chesterford, United Kingdom
Industry
Biotechnology
Employees
46
Funding
120.0M
Keywords

About CellCentric

Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.

CellCentric Contact Details

People in AeroLeads
4
With contact data
2
Email contacts
2
50.0% coverage
Phone contacts
1
25.0% coverage

CellCentric Org Chart

Sample employees and titles
Name Title Contact
Celia Economides
Email Phone
Jacob, Valeria Clinical Operations Director
View
Kris Frese Director of Cancer Biology
Email
Debbie Haynes Chief Operating Officer at Cellcentric
View

Employees by Management Level

Director 2 profiles
Executive 1 profile

Compare Similar Companies to CellCentric